Pfizer (NYSE:PFE) Given "Overweight" Rating at Cantor Fitzgerald

Pfizer (NYSE:PFE - Get Free Report)'s stock had its "overweight" rating reissued by equities research analysts at Cantor Fitzgerald in a report issued on Monday, Benzinga reports. They currently have a $45.00 target price on the biopharmaceutical company's stock. Cantor Fitzgerald's price objective would indicate a potential upside of 73.75% from the company's previous close.

Other equities analysts have also issued reports about the stock. TD Cowen lowered shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a "buy" rating and a $36.00 price objective on the stock. Finally, Argus cut Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $36.88.

Pfizer Stock Performance

NYSE PFE traded up $0.04 during trading on Monday, reaching $25.90. The company's stock had a trading volume of 35,623,531 shares, compared to its average volume of 42,737,133. Pfizer has a 12 month low of $25.61 and a 12 month high of $41.33. The firm has a 50 day moving average price of $27.28 and a 200 day moving average price of $28.88. The firm has a market capitalization of $146.66 billion, a price-to-earnings ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts' expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company's quarterly revenue was down 41.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.14 EPS. As a group, equities analysts anticipate that Pfizer will post 2.22 EPS for the current fiscal year.

Institutional Trading of Pfizer

A number of large investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. lifted its stake in Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company's stock valued at $157,215,000 after buying an additional 1,365,295 shares during the period. Brookstone Capital Management lifted its position in shares of Pfizer by 88.5% during the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company's stock valued at $14,109,000 after acquiring an additional 212,369 shares during the period. ETF Store Inc. boosted its stake in Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company's stock worth $214,000 after acquiring an additional 727 shares in the last quarter. Farmers Trust Co. grew its holdings in Pfizer by 2.0% in the fourth quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company's stock worth $6,503,000 after purchasing an additional 4,410 shares during the period. Finally, Wealthspire Advisors LLC raised its holdings in shares of Pfizer by 21.4% during the third quarter. Wealthspire Advisors LLC now owns 150,164 shares of the biopharmaceutical company's stock valued at $4,981,000 after purchasing an additional 26,455 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.